Research blog
Mechanism explainers, trial breakdowns, and sourcing notes from Peptides For Weight Loss. 6 articles on the compounds and receptor pathways behind the weight-loss peptide field.
Semaglutide vs tirzepatide: what the head-to-head trial shows
In SURMOUNT-5, tirzepatide produced a 20.2% mean weight change at 72 weeks versus 13.7% for semaglutide. Here is what that result can and cannot tell you.
Read the pieceWeight-loss peptides compared by the strength of human trial data
There is no single best weight-loss peptide, but there is a clear order of evidence. Tirzepatide and semaglutide lead; retatrutide and mazdutide follow.
Read the pieceThe pill that skips the needle: what an oral GLP-1 agonist changes about this field
Orforglipron is not a peptide, and that is the point. Here is why a small molecule that survives digestion could reshape sourcing, dosing, and research access for the entire GLP-1 class.
Read the pieceThe three-receptor race: why one weight-loss peptide just made the rest look outdated
Retatrutide adds a third receptor pathway most researchers did not expect to matter this much. Here is what that changes about the working theory of weight-loss peptides.
Read the pieceTwo receptors or three: what survodutide tests that retatrutide cannot
Retatrutide stacks GIP, GLP-1, and glucagon. Survodutide skips GIP entirely and pairs GLP-1 with glucagon alone. The difference is not a shortcut, it is a controlled way to isolate what glucagon is actually doing.
Read the pieceWhat a certificate of analysis actually proves, and what it does not
A COA with a 99% purity number on it looks conclusive. It is not, by itself. Here is what the document is actually verifying, what it leaves out, and the questions worth asking before trusting one.
Read the piece